The efficacy and safety of vildagliptin in the GALIANT trial: chronic kidney disease and other applications. Issue 2 (March 2011)

• Record Type: Journal Article
• Authors: Otterbeck, Philip E; Banerji, Mary Ann
• Is Part Of: Expert review of endocrinology & metabolism. Volume 6:Issue 2(2011)
• Page Start: 143
• Page End: 151
• Publication Date: 2011-03
• Subjects: dipeptidyl peptidase-4 inhibitors -- DPP-4 inhibitors -- GALIANT trial -- vildagliptin; Endocrinology -- Periodicals; Metabolism -- Periodicals; 616.4
• DOI: 10.1586/eem.11.6
• Languages: English
• ISSNs: 1744-6651

Abstract

The number of mechanistically novel antidiabetes agents has dramatically increased over the past few years. Dipeptidyl peptidase-4 (DPP-4) inhibitors in particular have emerged as clinically efficacious oral agents for diabetes management with a low incidence of side effects. The Galvus in Addition to Metformin versus Tzd/Metformin in Lowering HbA1c (GALIANT) trial showed that vildagliptin as an add-on therapy was noninferior to thiazolidinedione therapy with regard to reduction in hemoglobin A1c, with both drugs having a similar incidence of side effects in patients with normal and impaired renal function. DPP-4 inhibitors have a low incidence of hypoglycemia without significant weight gain and there is strong evidence that the administration of vildagliptin results in improved αα- and ββ-cell function. New data suggest that DPP-4 inhibitors might also have a role in the setting of myocardial infarction and lipid management, and in the prevention of Type 2 diabetes.